FRANKFORT, Ky. — Kentucky Governor Andy Beshear implemented an emergency ban on the sale of a dangerous synthetic drug known as “designer Xanax” on Monday, responding to a significant public health crisis. This decision follows a request from Attorney General Russell Coleman, who is spearheading a larger initiative aimed at curtailing the rising threat posed by this potent substance, which has been linked to numerous overdose fatalities in the state.
Coleman, along with a coalition of 21 attorneys general from various states, has urged the U.S. Drug Enforcement Administration (DEA) to take similar emergency measures at the federal level. In a collective letter, they highlighted the urgent need to address the unregulated drug, which has increasingly contributed to overdose deaths across the country. The attorneys general emphasized that without immediate action, the situation could worsen.
The drug at the center of this crisis, bromazolam, is being falsely marketed as legitimate prescription medications like benzodiazepines, commonly prescribed for anxiety, insomnia, and seizure disorders. However, bromazolam has never received approval for medical use in the United States or elsewhere, further endangering users who may mistake it for safe medication.
“There is zero margin of error when it comes to illicit drugs and counterfeit pills,” the attorneys general commented in their letter to DEA Administrator Terry Cole, underscoring the dire consequences of the drug’s availability. They urged parents and public officials to take decisive steps towards enforcement while promoting prevention and recovery initiatives that save lives.
In Kentucky, Beshear’s emergency regulation reclassifies bromazolam as a Schedule I controlled substance, allowing law enforcement to take action against those selling or possessing the drug. “This deadly drug has no place in our communities,” Beshear stated, emphasizing the importance of safeguarding citizens’ lives with these newfound regulatory tools.
The danger posed by bromazolam is particularly evident, as state officials reported its involvement in almost 50 overdose deaths in Kentucky last year. Although overall overdose deaths in the state have declined for three consecutive years, the emergence of this synthetic drug represents a troubling development in public health.
“There is a moment when as little as one pill can kill — and it is killing — our kids,” Coleman remarked, expressing gratitude for the collaborative efforts to confront this pressing issue.
In their letter to the DEA, the coalition described bromazolam as a highly potent substance that is available on both the streets and online. Its unpredictable effects become even more dangerous when combined with opioids or other central nervous system depressants. Unlike prescription medications, which are subject to rigorous quality controls, illicitly produced bromazolam can vary greatly in potency, heightening the risk for unsuspecting users.
The urgency of classifying bromazolam officially at the federal level was emphasized in the attorneys general’s correspondence. They argued that the failure to schedule this drug hampers law enforcement’s ability to tackle ongoing distribution efforts and poses challenges for public health officials responding to the crisis.
The unity displayed by these legal leaders is crucial as they seek not only to protect their communities but also to hold traffickers accountable. By calling on the DEA for emergency action, they hope to send a clear message that such hazardous substances have no place in society.
Coleman was not alone in this endeavor. His letter also included input from attorneys general from states such as Alabama, Florida, Texas, and West Virginia, highlighting the nationwide concern surrounding this emerging crisis. The collective response serves as a reminder of the ongoing battle against addiction and the necessity for proactive measures in preserving public health.